Exelixis sues MSN for generic CABOMETYX, asserting new patent expiring 2032

EXELIXIS, INC.

Filed patent infringement suit against MSN for generic CABOMETYX, asserting U.S. Patent No. 11,298,349 (expires Feb 10, 2032).
This is the fourth case; prior cases involve patents expiring Oct 8, 2030 and Jan 15, 2030, with trials in May 2022 (pending) and May 2023.
Exelixis seeks injunction to block FDA approval of MSN's ANDA until expiration of the asserted patents.
No trial date set for this new case; litigation ongoing in Delaware District Court.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.